Protective effect of green tea extract on the deltamethrin-induced toxicity in mice testis: An experimental study

Background: Deltamethrin (DM) is one of the environmental factors that can have destructive effects on the male fertility. Green tea (GT) as a medicinal herb, has antioxidant property. Objective: The present study investigated the protective role of GT extract in improving the harmful effects of DM on the testis. Materials and Methods: In this experimental study, 35 adult male mice (25–30 gr) were divided in to five groups (n = 7/each). The control group received only normal saline. Sham received 0.2 ml corn oil. Green tea group received only GT of 150 mg/kg. bw; deltamethrin group received the DM at a dose of 0.6 mg/kg. bw; GT + DM received both GT and DM. The effect of GT was assessed by measuring oxidative stress markers, sperm parameters, histological and immunohistochemical analysis. Results: The results showed that the count and motility of spermatozoa, testosterone, and Malondialdehyde significantly decreased (p < 0.001) and the abnormal spermatozoa increased (p < 0.001) in DM group compared to control group. Moreover, enhanced caspase-3expression and apoptosis were observed in DM-treated mice compared to control group. Histologically, DM with a degenerative effect on testicular tissue reduced the spermatogenesis progenitor cells. The epithelial height and the diameter of the seminiferous tubules were also reduced in the DM group. Treatment with GT in the DM-treated mice significantly improved these changes. Conclusion: With these findings, it was concluded that the GT treatment with antioxidant activity and anti-apoptotic property could protect the testicular injury induced by DM

Using of Naproxen drug for novel synthesis of 4-thiazolidinone derivatives and application of these drugs as no steroidal anti-inflammatory drug (NSAIDs) and as anti-epileptic agent

Non-steroidal anti-inflammatory drugs (NSAIDs) are now one of the most frequent drugs used in treatment of pain, inflammation and fever. In this study the aim is the synthesis of derivatives of 4-Tiazolidinon from naproxen with the possible anti-pain effects, and the main purpose of providing these derivatives is to achieve a compound with more anti-pain power and less side effects in comparison with applied drugs in clinics. Synthesis of these derivatives is done on chloride in presence of a group of new liquids like recyclable ionic liquids choline chloride, which the main advantages of these ionic liquids are the cheapness, availability, being non-toxic, and easy recyclability. This reaction was done in four stages. All the structures were verified by using data of spectrum testing, 1H-NMR, FT-IR

Comparative evaluation of the effect of Light Emitting Diode (LED) and Quartz Tungsten Halogen (QTH) light curing units on color stability of Filtek Z350 XT

Introduction: Discoloration of the resin-based composites is a common problem in restorative dentistry. There are many factors associatedwith the discoloration of dental materials in the oral environment. The purpose of this study was to evaluate the color changes in a nano-composite cured with a quartz-tungsten-halogen (QTH) and light emitting diode (LED) unit. Methods: 80 disk-shaped specimens were prepared using Filtek Z350 XT. The specimenswere cured with two LED units (Valo and BluephaseC5) andQTH )Astralis7(with two different energy density (400 & 750 mW/Cm²). The color of the materials was measured before and after immersingin tea and artificial saliva.Color change value (ΔE) were calculated and analyzed by 2-way ANOVA and Tukey’s test. Results:In artificial saliva group,the compositescured with Astralis7 and BluephaseC5 showed significantly more color stability. In tea group, the composites cured with BluephaseC5 significantly had the least color change. Conclusions:The type of light curing unitdoes not affectthe color stability. Exposure time and interaction between light source and photoinitiator content in composite may be the most important factors affecting color stability

Assessing oxidative stress resulting from environmental exposure to metals (Oids) in a middle Eastern population

Concentrations of metals and metalloids derived mainly from anthropogenic activities have increased considerably in the environment. Metals might be associated with increase reactive oxygen species (ROS) damage, potentially related to several health outcomes. This study has recruited 200 adult participants, including 110 males and 90 females in Shiraz (Iran), to investigate the relationship between chronic exposure to metals and ROS damage by analyzing malondialdehyde (MDA) and 8-Oxo-2'-deoxyguanosine (8-OHdG) concentrations, and has evaluated the associations between chronic metal exposure and ROS damage using regression analysis. Our findings showed participants are chronically exposed to elevate As, Ni, Hg, and Pb levels. The mean urinary concentrations of 8-OHdG and MDA were 3.8 ± 2.35 and 214 ± 134 µg/g creatinine, respectively. This study shows that most heavy metals are correlated with urinary ROS biomarkers (R ranges 0.19 to 0.64). In addition, regression analysis accounting for other confounding factors such as sex, age, smoking status, and teeth filling with amalgam highlights that Al, Cu, Si and Sn are associated with 8-OHdG concentrations, while an association between Cr and MDA and 8-OHdG is suggested. Smoking cigarettes and water-pipe is considered a significant contributory factor for both ROS biomarkers (MDA and 8-OHdG).peer-reviewe

Quantification of Health Impacts Related to PM10 and O3 Pollutants in Karaj City

Although the numbers of death related to air pollution appear to be low, the incidence of related disease to air pollution would be too high that is because of exposure of the large population to air pollutants and also the existence of certain sensitive groups. The aim of this study was to quantification health impacts of two pollutants PM10 and O3 in Karaj city during 2012- 2013. In this study, the air quality data were obtained from Karaj Department of Environment Protection. Quantification the health impacts of air pollutants were assessed using AirQ2.2.3 model which is a proposed method for assessing the health impact of air pollutants by World Health Organization. The annual, warm, and cold average concentrations of PM10 were 77.48, 87.86, and 62µg/m3, respectively. O3 average concentration in the warm semester was 63.5µg/m3 and it is more than a cold season which was 60µg/m3. Total mortality rate related to PM10 and O3 were assessed 282 and 164, respectively, which are 3.9 and 1.53 percent of all deaths, respectively. The Average cases of obstructive lung disease related to O3 were 58 people and average cases of hospitalization due to cardiovascular diseases related to PM10 were 492 people. This study was the first attempt to reveal the health outcome of air pollutants on a human in Karaj as one of the crowded city of Iran. Totally we found that the average concentration of 8-hours O3 and 24-hours PM10 were higher than the national standard of Iran and WHO guideline

Efficacy of 153Sm-EDTMP on Bone Pain Palliation in Metastatic Patients: Breast and Prostate Cancers

Purpose: This study aimed to evaluate the effect of samarium-153-EDTMP (153Sm-EDTMP) on pain relief bone metastases of Breast Cancer (BC) and Prostate Cancer (PC) patients. Materials and Methods: Thirty patients aged 40-77 years (62.6±10.2 years) with intractable metastatic bone pain were included in the current study. A checklist of patient information and a standard questionnaire for the assessment of pain and quality of life were completed before and after four and eight week’s palliative treatment with 37 MBq/kg of 153Sm-EDTMP. To analyse the data, parametric and non-parametric tests were used in SPSS software. Results: Twelve females with BC (40%) and 18 males with PC (60%) were included. Four and eight weeks after palliative treatment of 153Sm-EDTMP, the mean pain score reduction and quality of life were statistically increased compared to before the intervention (P-value 0.05). Conclusion: The injection of 153Sm-EDTMP had therapeutic efficacy for bone pain palliation in patients with diffuse bone metastases at the end of the 4th and 8th week post-infusion

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BackgroundDisorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021.MethodsWe estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined.FindingsGlobally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer.InterpretationAs the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation